Artemin reduces sensitivity to doxorubicin and paclitaxel in endometrial carcinoma cells through specific regulation of CD24

Translational Oncology

Volumn 3, Issue 4, 2010, Pages 218-229

  Pandey, Vijay ^a   Jung, Yewon ^a   Kang, Jian ^a   Steiner, Michael ^a   Qian, Peng Xu ^b   Banerjee, Arindam ^a   Mitchell, Murray D ^a,c   Wu, Zheng Sheng ^d   Zhu, Tao ^b   Liu, Dong Xu ^a   Lobie, Peter E ^a,e  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF QUEENSLAND   (Australia)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMIN; CD24 ANTIGEN; DOXORUBICIN; PACLITAXEL; PROTEIN ANTIBODY; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENICITY; CARCINOMA CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; MOUSE; NONHUMAN; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 77955666853     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.09325     Document Type: Article

References (42)

1. Ray M, and Fleming G (2009).Management of advanced-stage and recurrent endometrial cancer. Semin Oncol 36, 145-154.
2. Pandey V, Qian PX, Kang J, Perry JK, Mitchell MD, Yin Z, Wu ZS, Liu DX, Zhu T, and Lobie PE (2010). Artemin stimulates oncogenicity and invasiveness of endometrial carcinoma. Endocrinology 151, 909-920.
3. Ceyhan GO, Giese NA, Erkan M, Kerscher AG, Wente MN, Giese T, Buchler MW, and Friess H (2006). The neurotrophic factor artemin promotes pancreatic cancer invasion. Ann Surg 244, 274-281.
4. Kang J, Perry JK, Pandey V, Fielder GC, Mei B, Qian PX, Wu ZS, Zhu T, Liu DX, and Lobie PE (2009). Artemin is oncogenic for human mammary carcinoma cells. Oncogene 28, 2034-2045.
5. Kim KH, Choi JS, Kim JM, Choi YL, Shin YK, Lee HC, Seong IO, Kim BK, Chae SW, and Kim SH (2009). Enhanced CD24 expression in endometrial carcinoma and its expression pattern in normal and hyperplastic endometrium. Histol Histopathol 24, 309-316.
6. Kristiansen G, Sammar M, and Altevogt P (2004). Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 35, 255-262.
7. Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, and Petersen I (2003). CD24 is an independent prognostic marker of survival in nonsmall cell lung cancer patients. Br J Cancer 88, 231-236.
8. Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schluns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, et al. (2003). CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res 9, 4906-4913.
9. Kristiansen G, Denkert C, Schluns K, Dahl E, Pilarsky C, and Hauptmann S (2002). CD24 is expressed in ovarian cancer and is a new independent prognostic marker of patient survival. Am J Pathol 161, 1215-1221.
10. Boon K, Edwards JB, Siu IM, Olschner D, Eberhart CG, Marra MA, Strausberg RL, and Riggins GJ (2003). Comparison of medulloblastoma and normal neural transcriptomes identifies a restricted set of activated genes. Oncogene 22, 7687-7694.
11. Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, and Hollingsworth MA (2003). Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63, 5011-5020.
12. Nestl A, Von Stein OD, Zatloukal K, Thies WG, Herrlich P, Hofmann M, and Sleeman JP (2001). Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res 61, 1569-1577.
13. Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H, and Sleeman JP (2005). CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res 65, 10783-10793.
14. Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G, and Theodorescu D (2006). The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res 66, 1917-1922.
15. Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, and Arber N (2008). Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 68, 2803-2812.
16. Temkin SM and Fleming G (2009). Current treatment of metastatic endometrial cancer. Cancer Control 16, 38-45.
17. Pandey V, Perry JK, Mohankumar KM, Kong XJ, Liu SM,Wu ZS, Mitchell MD, Zhu T, and Lobie PE (2008). Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells. Endocrinology 149, 3909-3919.
18. Fukushima T, Tezuka T, Shimomura T, Nakano S, and Kataoka H (2007). Silencing of insulin-like growth factor-binding protein-2 in human glioblastoma cells reduces both invasiveness and expression of progression-associated gene CD24. J Biol Chem 282, 18634-18644.
19. Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, and Sakanaka C (2006). Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 25, 4361-4369.
20. Liu DX and Lobie PE (2007). Transcriptional activation of p53 by Pitx1. Cell Death Differ 14, 1893-1907.
21. Rahnama F, Shafiei F, Gluckman PD, Mitchell MD, and Lobie PE (2006). Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 147, 5275-5283.
22. Hao J, Song X, Song B, Liu Y, Wei L, Wang X, and Yu J (2008). Effects of lentivirusmediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther 15, 449-455.
23. Li S, Szymborski A, Miron MJ, Marcellus R, Binda O, Lavoie JN, and Branton PE (2009). The adenovirus E4orf4 protein induces growth arrest and mitotic catastrophe in H1299 human lung carcinoma cells. Oncogene 28, 390-400.
24. Kajiyama H, Shibata K, Terauchi M, Yamashita M, Ino K, Nawa A, and Kikkawa F (2007). Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31, 277-283.
25. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, and Corey SJ (2009). Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101, 38-47.
26. Engel JB, Schonhals T, Weidler C, Hausler S, Krockenberger M, Rieger L, Dietl J, Wischhusen J, and Honig A (2009). Tubulin inhibitor AEZS 112 inhibits the growth of experimental human ovarian and endometrial cancers irrespective of caspase inhibition. Oncol Rep 22, 361-367.
27. Etienne-Manneville S, Manneville JB, Adamson P, Wilbourn B, Greenwood J, and Couraud PO (2000). ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol 165, 3375-3383.
28. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, and Boven E (2006). Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 5, 2348-2357.
29. Rosenblum MD and Shivers RR (2000). "Rings" of F-actin form around the nucleus in cultured human MCF7 adenocarcinoma cells upon exposure to both taxol and taxotere. Comp Biochem Physiol C Toxicol Pharmacol 125, 121-131.
30. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, Hahn WC, Ishikawa F, and Lee HW (2008). TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 27, 3754-3760.
31. Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X, Di Cristofano A, Pandolfi PP, and Hay N (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev 20, 1569-1574.
32. Dai D, Litman ES, Schonteich E, and Leslie KK (2003). Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 87, 123-131.
33. Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, and Pecorelli S (2005). Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104, 1391-1397.
34. Fleming GF, Filiaci VL, Bentley RC, Herzog T, Sorosky J, Vaccarello L, and Gallion H (2004). Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol 15, 1173-1178.
35. Karahan N, Guney M, Oral B, Kapucuoglu N, and Mungan T (2006). CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol 27, 500-504.
36. Kristiansen G, Pilarsky C, Pervan J, Sturzebecher B, Stephan C, Jung K, Loening S, Rosenthal A, and Dietel M (2004). CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate 58, 183-192.
37. Surowiak P, Materna V, Paluchowski P, Matkowski R, Wojnar A, Maciejczyk A, Pudelko M, Kornafel J, Dietel M, Kristiansen G, et al. (2006). CD24 expression is specific for tamoxifen-resistant ductal breast cancer cases. Anticancer Res 26, 629-634.
38. Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, and Reisfeld RA (2006). Characterization of stem cell-like cancer cells in immune-competent mice. Blood 108, 3906-3912.
39. Lee CJ, Dosch J, and Simeone DM (2008). Pancreatic cancer stem cells. J Clin Oncol 26, 2806-2812.
40. Li J, Klein C, Liang C, Rauch R, Kawamura K, and Hsueh AJ (2009). Autocrine regulation of early embryonic development by the artemin-GFRA3 (GDNF family receptor-alpha 3) signaling system in mice. FEBS Lett 583, 2479-2485.
41. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, and Weinberg RA (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40, 499-507.
42. lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother 58, 1185-1194.